| 1 |
What is the primary function of AI in the medical imaging industry?
|
To conduct medical research |
|
makes it possible for machines to learn from experience, adjust to new inputs and perform human-like tasks. |
What is the primary function of AI? |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Increases the need for radiologists |
|
increased diagnostic accuracy |
The primary benefits of using AI in radiology include increased diagnostic accuracy. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
the ability to recognize, grasp, use, and critically assess artificial intelligence technologies and their impacts. |
What does AI literacy mean? |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
Trust in AI systems |
|
Data privacy and security risks through the generation of vast amounts of sensitive patient data. |
Why is AI not used in healthcare? |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Determines the financial budget for AI |
|
help answer questions about medications, forward reports to doctors or surgeons and help patients schedule a visit with a physician. |
How does AI play a role in healthcare? |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
The attitudes about the usage of artificial intelligence in healthcare are controversial. Unlike the perception of healthcare. |
Attitudes and perception of artificial intelligence in healthcare: A cross-sectional survey among patients. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
Increasing AI acceptability among medical professionals will critically require designing human-centred AI systems which go beyond high algorithmic performance to consider accessibility to users with varying degrees of AI literacy, clinical workflow practices, the institutional and deployment context, and the cultural. |
Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
value proposition, self-efficacy, burden, and workflow integration. |
Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
privacy and surveillance, bias and discrimination, as well as the role of human judgement. |
What are the ethical implications of AI in healthcare? |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
experiments and surveys |
What is the research methodology of AI? |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
replace the failing dopaminergic neurons. |
Parkinson’s disease causesTrusted Source the loss of dopaminergic neurons. These neurons help release and regulate dopamine, which playsTrusted Source a key role in many different bodily functions, especially those involving movement, thinking, motivation, and mood.
Stem cell therapy aims to replace the failing dopaminergic neurons. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
A rat model of cerebral small vascular disease induced by ultrasound and protoporphyrin. |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
STEM-PD shows no adverse effects or tumor formation in rats up to 9 months. |
Cell Stem Cell. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
Cell replacement therapies for Parkinson’s disease (PD) based on transplantation of pluripotent stem cell- derived dopaminergic neurons are now entering clinical trials. Here, we present quality, safety, and efficacy data supporting the first-in-human STEM-PD phase I/IIa clinical trial along with the trial design. |
Cell replacement therapies for Parkinson’s disease (PD) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
GMP manufacturing of cryopreserved dopamine progenitor cell product STEM-PD from hESCs |
Clinical and Translational Report. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
Importantly, no adverse effects were observed upon testing of the product in a 39-week rat GLP safety study for toxicity, tumorigenicity, and biodistribution, and a non-GLP efficacy study confirmed that the transplanted cells mediated full functional recovery in a pre-clinical rat model of PD. |
a non-GLP efficacy study. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells increased cognitive impairments. |
|
to replace damaged or dysfunctional cells in the hope of restoring functioning and slowing or reversing the progress of Parkinson's disease. |
Parkinson's disease. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
FOXA2 and OTX2 |
|
Results from flow cytometric release analysis of batch #3 for purity markers FOXA2 and OTX2. |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are irrelevant to the process. |
|
Individual nuclei were isolated from tissue transplanted to the striatum (3 and 6 months) or the nigra (at 6, 9, and 12 months after transplantation) using a dounce homogenizer and nuclei lysis buffer. This suspension was sorted based on size using the BD FACSAria III Cell Sorter to remove cell debris and fractured nuclei. 7-10,000 nuclei per sample were loaded onto a 10x Chromium Next GEM Chip G following the manufacturer’s instructions and processed in a Chromium controller (both 10x Genomics, Pleasan- ton, USA). Briefly, after encapsulating single nuclei with barcoded bead. |
Individual nuclei were isolated from tissue transplanted to the striatum (3 and 6 months) or the nigra (at 6, 9, and 12 months after transplantation) using a dounce homogenizer and nuclei lysis buffer. This suspension was sorted based on size using the BD FACSAria III Cell Sorter to remove cell debris and fractured nuclei. 7-10,000 nuclei per sample were loaded onto a 10x Chromium Next GEM Chip G following the manufacturer’s instructions and processed in a Chromium controller (both 10x Genomics, Pleasan- ton, USA). Briefly, after encapsulating single nuclei with barcoded bead. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
dosing and toxicity levels. |
efficacy is measured under expert supervision in a group of patients most likely to have a response to a drug, such as in a controlled clinical trial. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|